Department of Medicine

University of Pittsburgh

Julien J. Fourcade, PharmD, PhD

photo

Research Instructor

Office: L1.33 Hillman Cancer Center
5117 Centre Ave
Pittsburgh, PA 15213
 
Phone:
Fax:
E-mail: fourcadejj@upmc.edu

Education
Pharm.D., University Paul Sabatier, Toulouse, France, 2003
Ph.D. in Oncology/Immunology, University of Aix-Marseille, France, 2012

Training
Postdoctoral Associate, University of Pittsburgh, 2006

Area of Specialization/Research Interest  
Cancer Immunology
Cancer Immunotherapy
Cancer vaccines
Tumor antigen-specific T cell biology
Tumor-induced immunosuppression
Immunologic checkpoints in cancer immunotherapies
 

Profile
Dr Fourcade's research activities are focused on the study of spontaneous and vaccine-induced T cell immune responses against melanoma and other solid tumors in cancer patients, and their interaction with other immune cell subsets involved in anti-tumor immunity. Dr Fourcade is also particularly involved in the study of the multiple mechanisms leading to tumor-induced immunosuppression in cancer patients, including the study of expression and functions of co-inhibitory receptors (ex: PD-1, BTLA, Tim-3) by tumor antigen (TA)-specific T cells and other immune cell subsets involved in anti-tumor immunity,the study of agents designed to target immunologic checkpoints and reverse tumor-induced TA-specific T cell dysfunction/exhaustion and the study of TA-specific Tregs.
His research also includes the identification of novel immunogenic antigens expressed by tumors and the clinical and immunological evaluation of new adjuvants that may help to optimize vaccines in cancer patients.

Recent Peer-Reviewed Publications
Title: Strategies to reverse melanoma-induced T-cell dysfunction.
Author(s): Fourcade J, Zarour HM
Year: 2013
Journal: Clin Dermatol. 2013 May-Jun;31(3):251-6.
Volume:
Page(s):
Title: CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1.
Author(s): Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM
Year: 2012
Journal: Cancer Res. 2012 Feb 15;72(4):887-96
Volume:
Page(s):
Title: Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
Author(s): Kudela P, Sun Z, Fourcade J, Janjic B, Kirkwood JM, Maillere B, Zarour HM
Year: 2011
Journal: J Immunol. 2011 Jan 1;186(1):312-22
Volume:
Page(s):
Title: Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
Author(s): Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM
Year: 2010
Journal: J Exp Med. 2010 Sep 27;207(10):2175-86.
Volume:
Page(s):
Title: Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire.
Author(s): Fourcade J, Sun Z, Kudela P, Janjic B, Kirkwood JM, El-Hafnawy T, Zarour HM
Year: 2010
Journal: J Immunol. 2010 Jun 15;184(12):6709-18.
Volume:
Page(s):
Title: PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
Author(s): Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM.
Year: 2009
Journal: J Immunol. 2009 May 1;182(9):5240-9.
Volume:
Page(s):
Title: Immunization with analogue peptide in combination with CpG and Montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
Author(s): Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM.
Year: 2008
Journal: J Immunother. 2008 Oct;31(8):781-91.
Volume:
Page(s):
Title: Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients.
Author(s): Kudela P, Janjic B, Fourcade J, Castelli F, Andrade P, Kirkwood JM, El-Hefnawy T, Amicosante M, Maillere B, Zarour HM.
Year: 2007
Journal: J Immunol. 2007 Dec 1;179(11):7932-40.
Volume:
Page(s):
Title: Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers.
Author(s): Janjic B, Andrade P, Wang XF, Fourcade J, Almunia C, Kudela P, Brufsky A, Jacobs S, Friedland D, Stoller R, Gillet D, Herberman RB, Kirkwood JM, Maillere B, Zarour HM.
Year: 2006
Journal: J Immunol. 2006 Aug 15;177(4):2717-27.
Volume:
Page(s):
Title: In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase.
Author(s): Holleran JL, Fourcade J, Egorin MJ, Eiseman JL, Parise RA, Musser SM, White KD, Covey JM, Forrest GL, Pan SS.
Year: 2004
Journal: Drug Metab Dispos. 2004 May;32(5):490-6.
Volume:
Page(s):